

THIS REPORT HAS BEEN DELIMITED
AND CLEARED FOR PUBLIC RELEASE
UNDER DOD DIRECTIVE 5200.20 AND
NO RESTRICTIONS ARE IMPOSED UPON
ITS USE AND DISCLOSURE.

DISTRIBUTION STATEMENT A

APPROVED FOR PUBLIC RELEASE;
DISTRIBUTION UNLIMITED.

Armed Services Technical Information Agency

Because of our limited supply, you are requested to return this copy WHEN IT HAS SERVED YOUR PURPOSE so that it may be made available to other requesters. Your cooperation will be appreciated.

AD

38538

NOTICE: WHEN GOVERNMENT OR OTHER DRAWINGS, SPECIFICATIONS OR OTHER DATA ARE USED FOR ANY PURPOSE OTHER THAN IN CONNECTION WITH A DEFINITELY RELATED GOVERNMENT PROCUREMENT OPERATION, THE U. S. GOVERNMENT THEREBY INCURS NO RESPONSIBILITY, NOR ANY OBLIGATION WHATSOEVER; AND THE FACT THAT THE GOVERNMENT MAY HAVE FORMULATED, FURNISHED, OR IN ANY WAY SUPPLIED THE SAID DRAWINGS, SPECIFICATIONS, OR OTHER DATA IS NOT TO BE REGARDED BY IMPLICATION OR OTHERWISE AS IN ANY MANNER LICENSING THE HOLDER OR ANY OTHER PERSON OR CORPORATION, OR CONVEYING ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE OR SELL ANY PATENTED INVENTION THAT MAY IN ANY WAY BE RELATED THERETO.

Reproduced by
DOCUMENT SERVICE CENTER
KNOTT BUILDING, DAYTON, 2, OHIO

UNCLASSIFIED

AD NO. 38538

ASTIA FILE COPY

FINAL REPORT

George H. Scherr

June 30, 1954

NONR 727(01)

Contract No. NONR 717 (00)

The Creighton University, School of Medicine
Omaha, Nebraska

Title of Project: The Therapy of Systemic Moniliasis in Mice

Observations that pregnant mice showed a higher degree of resistance to infection with Candida albicans than non-pregnant females or males (Scherr and Weaver, 1951) prompted an investigation of the effects of various gonadotropic hormones on male and female mice infected with moniliasis. By controlling and altering the types of gonadotropins used, route of injection of hormones, severity of infection, dosage amount, and schedule of treatment, it was found that it was possible to significantly decrease the severity of the infection upon treatment with certain gonadotropins, under rather exacting conditions. Tables 1 to 5 inclusive summarize these results for the various gonadotropic hormones used, including whole pregnant mouse serum; the mean dissemination values are computed as previously described (Scherr, 1953c).

On the basis of observations such as that of Sehval and Soffer (1951) indicating that treatment with cortisone may increase the titer of urinary gonadotropins, studies were undertaken to ascertain the effect of cortisone and/or somatotrophic hormones (STH) on Candida-infected mice.

It was found that under certain conditions cortisone would significantly reduce the mortality rate of infected animals but to varying degrees depending among other factors, upon the sex of the animal. These results and other pertinent data are presented in greater detail in other papers (Scherr, 1953a, 1953b, 1953c, 1953d, 1953f). They are in accord with findings of other

THIS REPRESENTS A TECHNICAL REPORT SUBMITTED IN
CONNECTION WITH OFFICE OF NAVAL RESEARCH
PROJECT NR 132-116

investigators working with other infectious agents (Duffy and Morgan, 1951; Kilbourne, 1952; Robinson et. al., 1953).

The physiological antagonism between STH and cortisone was corroborated under the conditions of these studies and in a manner which supported our thesis that cortisone may be deleterious or efficacious to certain infectious states depending upon the conditions and environment of the infected host. It should be possible, by a suitable control of these conditions, to preferentially antagonize the deleterious properties of cortisone without suppressing its efficacious effect. The practical possibility of this approach to the therapy of certain infectious states gained some support from studies using mice infected with moniliasis (Scherr, 1953d, 1953e) and embryonated eggs infected with vaccinia virus (Severens et. al., 1954; Scherr et. al., 1954).

Because the sex of the animal plays a major role in the response of infected and uninfected mice to treatment with cortisone and/or STH (Scherr, 1952, 1953d), studies were undertaken to ascertain the influence of sex hormones, either alone or in combination with cortisone and STH, on this infectious state. These data are summarized in the tables 6, 7, and 8 and have been presented in greater detail in other papers (Scherr, 1954a).

One of the most significant features of these results is that testosterone enhanced the deleterious effect of cortisone on infected male and female mice and that this synergistic deleterious effect increased with an increased dosage of testosterone. In addition, a mixture of cortisone and testosterone, at dosage levels which had no toxic effect on normal mice when used alone, resulted in a mortality of 40% when inoculated into normal male animals. This toxic effect of the mixture was suppressed to a very slight degree by the dosage of STH used here.

The study reported here is in accord with the precept that there is an interplay of adrenal-cortical and other hormones which tends to maintain a state of resistance or susceptibility to infectious diseases. This activity is essentially non-specific and affects the resistance of the host through the effect on numerous bodily functions, e.g., capillary fragility, inflammatory response, antibody formation, salt and fluid balance, and many others. If alteration in the performance of these bodily functions by induced changes in the concentrations of various hormones enhances the susceptibility of the host to infection with certain pathogenic agents, then it should be feasible to suppress active infectious states by exerting an influence on the above-mentioned bodily functions by judicious injections of proper kinds and concentrations of certain hormones and other agents. It has thus been possible to show that a particular dose schedule of cortisone, STH, and hesperedin methyl chalcone almost completely obliterated any signs of experimental moniliasis in female mice but not in males, and that this same treatment schedule was ineffective for both sexes when the severity of the infection was altered (Scherr, 1954b).

Table 1
 Effect of Normal Pregnant Mouse Serum on Mice Infected
 with Monilliasis
 (Duration of experiment - 15 days)

Legend	Sex	No. Mice	Mean dissi mination value	Averaged mean value
Infected, untreated	M	5	4.2	4.1
	F	4	4.0	
Infected, treated daily with 0.2 ml of pregnant mouse serum	M	5	1.0	1.6
	F	5	2.2	

t 4.44
 Deg. of freedom 17
 P , / .005

Table 2

Effect of Gonadotropin from Pregnant Mare's Serum (Gonadogen)

on Mice Infected with Moniliasis

(Duration of experiment = 23 days)

Infected mice treated with Gonadogen	No. Mice	Sex	Mean disse- mination value	Mortality (%)
Untreated (4-73A)	30	M	1.0	0.0
0.4 I.U. (0.1 ml) per mouse per day, subcut., treatment started day after 30 infection (4-73E)		M	2.1	10.0
Treated as in 4-73E but started 15 days after infection (4-74A)	26	M	5.0	34.6
Treated as in 4-73E but dose doubled every 6 days (4-74I)	30	M	4.3	23.4
Untreated (4-73B)	30	F	1.4	3.3
Treated as in 4-73E (4-73F)	30	F	1.4	3.3
Treated as in 4-74A (4-74B)	26	F	4.3	26.9
Treated as in 4-74I (4-74J)	30	F	1.3	3.3
Infected with mucin adjuvant, untreated (4-73C)	30	M	8.7	50.0
Infected as in 4-73C, treated as in 4-73E (4-73G)	28	M	8.8	46.4
Infected as in 4-73C, treated as in 4-74A (4-74C)	59	M	8.9	50.9
Infected as in 4-73C, untreated (4-73D)	30	F	8.6	46.7
Infected as in 4-73C, treated as in 4-73E (4-73H)	20	F	8.4	46.7
Infected as in 4-73C, treated as in 4-74A (4-74D)	59	F	7.0	45.8

Table 3

Effect of Gonadotropin from Pregnant Mare's Serum (Gonadogen)

on Mice Infected with Moniliasis

(Duration of experiment = 23 days)

Infected mice treated with Gonadogen	No. mice	Sex	Mean diss- emination value	Mortality (%)
1.6 I. U. (0.1 ml) per mouse per day, subcut., treatment started day after infection (4-82E)	60	M	6.5	35.0
Treated as in 4-82E but treatment started 15 days after infection (4-82M)	58	M	4.1	29.3
Treated as in 4-82E but dose doubled every 6 days (4-83H)	30	M	11.3	60.0
Untreated (4-82B)	30	F	3.2	20.0
Treated as in 4-82E (4-82F)	60	F	6.4	33.3
Treated as in 4-82E but treatment started 15 days after infection (4-83A)	60	F	4.4	23.4
Treated as in 4-82E but dose doubled every 6 days (4-83I)	30	F	9.4	46.7
Infected with mucin adjuvant, untreated (4-82C)	30	M	23.2	100.0
Infected as in 4-82C, treated as in 4-82E (4-82O)	60	M	21.1	93.3
Infected as in 4-82C, treated as in 4-82M (4-83B)	60	M	21.8	95.0
Infected as in 4-82C, treated as in 4-82E but dose doubled every 6 days (4-83J)	29	M	15.0	62.1

Table 3 (cont'd)

Infected mice treated with Gonadogen	No. mice	Sex	Mean diss- emination value	Mortality (%)
Infected as in 4-82C, untreated (4-82D)	30	F	25.9	100.0
Infected as in 4-82C, treated as in 4-82E (4-82H)	60	F	22.2	91.8
Infected as in 4-82C, treated as in 4-82H (4-83C)	60	F	24.7	90.0
Infected as in 4-82C, treated as in 4-82E but dose doubled every 6 days (4-83K)	30	F	9.1	53.3
Infected as in 4-82C, treated with 0.4 I. U. (0.1 ml) Gonadogen per mouse per day, subcut., dose doubled every 6 days (4-83L)	30	M	15.6	66.7
Infected as in 4-82C, treated as in 4-83L (4-83M)	30	F	14.0	60.0

Table 4

The Effect of Gonadotropin from Human Pregnancy Urine

(Pranturon) on Experimental Moniliasis in Mice

(Duration of experiment = 25 days)

Legend ¹	Sex	Mean diss- emination value	Mortality (%)
Infected, untreated (4-13B)	M	20.5	70.0
Infected, treated with 0.8 I. U. (0.1 ml) intramuscularly (4-13D)	M	19.8	70.0
Infected, treated with 1.6 I.U. (0.2 ml) intramuscularly (4-13F)	M	23.9	90.0
Uninfected, treated with 1.6 I.U. (0.2 ml) intramuscularly (4-13H)	M	4.0	20.0
Infected, untreated (4-13I)	F	19.5	70.0
Infected, treated as in 4-13D (4-13L)	F	3.3	20.0
Infected, treated as in 4-13F (4-13N)	F	17.0	60.0
Uninfected, treated as in 4-13F (4-13P)	F	0.0	0.0
Infected, treated with 0.8 I.U. (0.1 ml) subcut. (4-14B)	M	20.6	90.0
Infected, treated with 1.6 I.U. (0.2 ml) subcut. (4-14D)	M	20.0	80.0
Infected, treated with 0.8 I.U. (0.1 ml) subcut. (4-14H)	F	22.6	80.0
Infected, treated with 1.6 I.U. (0.2 ml) subcut. (4-14J)	F	24.6	90.0
Uninfected, treated as in 4-14J (4-14E)	M	4.7	20.0
Uninfected, treated as in 4-14J (4-14K)	F	3.3	20.0
Uninfected, inoculated solely with mucin adjuvant (4-13G)	M	2.6	10.0

Table 4 (cont'd)

Legend	Sex	Mean disse- mination value	Mortality (%)
Uninfected, inoculated solely with mucin adjuvant (4-130)	F	2.2	10.0

t comparing 4-13I to 4-13L 3.6
P 0.001

¹ Treatment with Pranturon using the 5 per cent mucin adjuvant, was in all cases instituted 2 days after infection and repeated daily for the duration of the experiment. Ten mice constitute an experimental group in every case.

Table 5

The Effect of Gonadotropin from Pregnant Mare Serum

(Anteron) on Experimental Moniliae in Mice

(Duration of experiment - 29 days)

Legend ¹	Sex	Mean diss- emination value	Mortality (%)
Infected, untreated (3-230D)	M	10.4	80.0
Infected, treated (3-240F)	M	11.6	30.0
Infected, untreated (3-239D)	F	5.1	10.0
Infected, treated (3-239F)	F	3.1	10.0
Uninfected, treated as above (3-219E)	M	0.0	0.0
Uninfected, treated as above (3-239H)	F	0.0	0.0
Infected with mucin adjuvant, untreated (3-240E)	M	16.0	70.0
Infected as in 3-240E, treated (3-240G)	M	8.1	30.0
Infected as in 3-240E, untreated (3-239E)	F	18.0	60.0
Infected as in 3-240E, treated (3-239G)	F	10.2	50.0
Uninfected, inoculated with mucin adjuvant only (4-239I)	F	0.0	0.0

t comparing groups 3-240E and 3-240G 2.86
 P 0.02 0.01

¹ Treatment consisted of the intramuscular inoculation of 0.8 I.U. (0.1 ml) of the anteron, which in all cases was instituted 2 days after infection and repeated daily for the duration of the experiment. Ten mice constitute an experimental group.

Table 6

The Effect of Cortisone, Somatotrophic Hormone (STH),
and Testosterone on Experimental Moniliasis in
Mice

(Duration of Experiment = 29 days)		Mean Dissemination		Mortality (%)
Infected mice treated with 1	No. Mice	Sex	value	
Untreated (4-122A)	20	M	6.3	30.0
Testosterone (4-123A)	20	M	7.9	30.0
Testosterone (2x), (4-159E)	19	M	6.5	25.0
Testosterone & cortisone (4-122S)	20	M	15.9	85.0
Testosterone (2x) & cortisone (4-159c)	20	M	18.8	95.0
Cortisone (4-122E)	20	M	12.7	80.0
Testosterone & STH (4-122U)	20	M	6.8	40.0
STH (4-122C)	20	M	11.1	55.0
Cortisone, testosterone, & STH (4-122W)	20	M	10.6	65.0
Cortisone & STH (4-122G)	20	M	14.5	90.0
Untreated (4-122B)	20	F	3.4	10.0
Testosterone (4-123B)	20	F	16.2	85.0
Testosterone (2x), (4-159F)	(no data available)			
Testosterone & cortisone (4-122T)	20	F	11.5	70.0
Testosterone (2x) & cortisone (4-159D)	20	F	15.7	85.0
Cortisone (4-122F)	20	F	11.1	65.0
Testosterone & STH (4-122V)	20	F	7.9	40.0
STH (4-122D)	20	F	7.0	40.0
Cortisone, STH, & testosterone (4-122X)	20	F	10.3	55.0
Cortisone & STH (4-122H)	20	F	10.8	70.0

Table 6 (cont'd)

¹ For details of treatment schedules see text. In order to facilitate the presentation and discussion of these and other data which follow, each group of animals has been assigned a code number.

Table 7

The Effect of Cortisone, Somatotrophic Hormone (STH),
and Testosterone on Normal Mice ¹

Uninfected mice treated with	No. mice	Sex	Mean Dissemination value	Mortality (%)
Testosterone 9(4-159W)	20	M	0.0	0.0
Testosterone & Cortisone (4-159Q)	20	M	7.3	40.0
Cortisone (4-123S)	20	M	0.0	0.0
Testosterone & STH (4-159S)	20	M	7.4	30.0
STH (4-158C)	20	M	11.2	50.0
Testosterone, cortisone, & STH (4-159U)	20	M	4.6	35.0
Cortisone & STH (4-158E)	20	M	1.9	10.0
Testosterone (4-159X)	20	F	0.0	0.0
Testosterone & cortisone (4-159R)	20	F	0.3	5.0
Cortisone (4-123T)	20	F	0.0	0.0
Testosterone & STH (4-159T)	20	F	5.6	25.0
STH (4-158D)	20	F	2.3	15.0
Testosterone, cortisone, & STH (4-159V)	20	F	0.5	5.0
Cortisone & STH (4-158F)	20	F	4.1	20.0

¹ These animals were treated simultaneously with and similarly to those described in Table 1.

Table 8
The Effect of Cortisone, Somatotrophic Hormone (STH),
and Estradiol on Experimental Moniliasis in Mice
(Duration of experiment = 29 days)

Infected mice treated with ¹	No. mice	Sex	Mean Dissemination value	Mortality (%)
Estradiol (4-123I)	20	M	15.2	70.0
Estradiol & cortisone (4-123C)	20	M	11.0	70.0
Estradiol & STH (4-123E)	19	M	3.6	10.5
Cortisone, estradiol, & STH (4-123G)	20	M	15.9	75.0
Estradiol (4-123J)	20	F	3.1	10.0
Estradiol & cortisone (4-123D)	20	F	17.0	90.0
Estradiol & STH (4-123F)	20	F	20.1	75.0
Cortisone, estradiol, & STH (4-123H)	20	F	19.1	90.0

¹ For details of treatment schedules see text. Control data for infected and normal male and female mice treated with cortisone and/or STH are recorded in Table 1 and 2.

REFERENCES

- Duffy, B. J. and H. R. Morgan 1951 Proc. Soc. Exp. Biol. and Med., 78:687.
- Kilbourne, E. D. 1952 J. Clin. Investigation, 31: 643.
- Robinson, H. J., R. C. Mason, and Amelia L. Smith 1953 Proc. Soc. Exp. Biol. and Med., 84: 312.
- Scherr, G.H. and R. H. Weaver 1951 Bact. Proceedings, 113.
- Scherr, G.H. 1952 Science, 116:685.
- Scherr, G.H. 1953a Mycologia, 45,359.
- Scherr, G.H. 1953b Proc. Nebraska Acad. Sci., 7.
- Scherr, G.H. 1953c Mycopathologia, 6:325.
- Scherr, G.H. 1953d Ibid., 6:337.
- Scherr, G.H. 1953e Bact. Proceedings, 72.
- Scherr, G.H. 1953f Riassunti delle Comunicazioni, VI Congresso Internaz. di Microbiol., II, 102.
- Scherr, G.H. 1954a Bact. Proceedings, 86.
- Scherr, G.H. 1954b Proc. Nebraska Acad. Sci., 9.
- Scherr, G.H., J.M. Severens, P. Jurtshuk, Jr., and C.L. Wittenberger 1954 J. Infect. Dis., In Press.
- Severens, J.M., G. H. Scherr, C. L. Wittenberger, and P. Jurtshuk, Jr. 1954 Bact. Proceedings, 69.
- Sohval, A. R. and L. J. Soffer 1951 J. Clin. Endocrinology, 11:677

Armed Services Technical Information Agency

Because of our limited supply, you are requested to return this copy WHEN IT HAS SERVED YOUR PURPOSE so that it may be made available to other requesters. Your cooperation will be appreciated.

AD

38538

NOTICE: WHEN GOVERNMENT OR OTHER DRAWINGS, SPECIFICATIONS OR OTHER DATA ARE USED FOR ANY PURPOSE OTHER THAN IN CONNECTION WITH A DEFINITELY RELATED GOVERNMENT PROCUREMENT OPERATION, THE U. S. GOVERNMENT THEREBY INCURS NO RESPONSIBILITY, NOR ANY OBLIGATION WHATSOEVER; AND THE FACT THAT THE GOVERNMENT MAY HAVE FORMULATED, FURNISHED, OR IN ANY WAY SUPPLIED THE SAID DRAWINGS, SPECIFICATIONS, OR OTHER DATA IS NOT TO BE REGARDED BY IMPLICATION OR OTHERWISE AS IN ANY MANNER LICENSING THE HOLDER OR ANY OTHER PERSON OR CORPORATION, OR CONVEYING ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE OR SELL ANY PATENTED INVENTION THAT MAY IN ANY WAY BE RELATED THERETO.

Reproduced by
DOCUMENT SERVICE CENTER
KNOTT BUILDING, DAYTON, 2, OHIO

UNCLASSIFIED